Drugs / Cefpodoxime
Cefpodoxime
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00143533 | Sep 2003 → Sep 2010 | diarrheal disease, neoplasm | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06406114 | May 2025 → Jul 2028 expected | anaphylaxis, drug allergy, drug pseudoallergy | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03590912 | Sep 2018 → Feb 2020 | otitis media with effusion | Lumbini Medical College | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT03098485 | Jan 2017 → Aug 2022 | — | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT00194532 | Jun 2005 → Feb 2009 | cystitis | University of Washington | Completed | No outcome recorded |
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00786669 Background | Oct 2008 → Nov 2012 | cancer | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 1 | NCT00186979 Background | May 2003 → Mar 2010 | cancer | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05384197 Comparator | May 2022 → May 2023 | nephrolithiasis | Mansoura University | Unknown | No outcome recorded |
| Phase 3 | NCT03729258 Comparator | May 2019 → Oct 2023 | sinusitis | Neutec Ar-Ge San ve Tic A.Ş | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05977868 Background | Aug 2023 → Feb 2025 | digestive system infectious disorder | West Virginia University | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cefpodoxime | “8 mg/kg/day (max. daily dose 400 mg) of cefixime or 5 mg/kg/dose bid (max. daily dose 400 mg) of cefpodoxime starting Day -1 BEFORE chemotherapy and continuing EVERY DAY while...” NCT00786669 ↗9“Children in this group will be treated with antiboitics (syp cefpodoxime) at 10 mg/kg/day in two divided dose for a week” NCT03590912 ↗ “Infex (cefpodoxime) 400mg once a day (QD) for 10 days” NCT03729258 ↗ “200 mg Cefpodoxime twice daily” NCT05384197 ↗ |
| Known as | Cefpodoxima | ChEMBL registry synonym — accepted as the source's own label CHEMBL1672 ↗ |
| Known as | Epoxim | ChEMBL registry synonym — accepted as the source's own label CHEMBL1672 ↗ |
| Known as | Infex | “Infex (cefpodoxime) 400mg once a day (QD) for 10 days” NCT03729258 ↗ |
| Known as | Orelox paed | ChEMBL registry synonym — accepted as the source's own label CHEMBL1672 ↗ |
| Modality | Small molecule | — CHEMBL1672 ↗ |
| Route | Oral | “Cefpodoxime will be given orally at 10 mg/kg/day divided BID” NCT00143533 ↗ |